GOSSGossamer Bio, Inc.

Gossamer Bio, Inc. (NASDAQ: GOSS) | Price: $10.59 | Today's Change: -7.08%

---

What Happened

Gossamer Bio filed an 8-K with the SEC on September 11, 2026, covering Items 3.03, 5.03, 8.01, and 9.01 — a combination that signals material changes to securities, amendments to the company's articles or bylaws, and other reportable events alongside attached financial exhibits. The filing includes Q2 FY2026 financial results showing revenue of $21,378,000 against a net loss of $36,638,000 and a shareholder-level operating loss of $75,575,000. Basic and diluted loss per share both came in at -$0.33 for the quarter.

---

Why It Matters

The multi-item nature of this 8-K — spanning Items 3.03 (Material Modification to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws), and 8.01 (Other Events) — suggests this filing goes beyond routine financial disclosure. Changes to security holder rights and corporate governance documents can have direct implications for existing shareholders, potentially affecting voting rights, share structures, or protective provisions. Meanwhile, the underlying financials tell their own story: a $75.6 million operating loss against just $21.4 million in revenue in a single quarter underscores the significant cash consumption rate at this clinical-stage company. With shares already down more than 7% on the day, the market is clearly treating this disclosure as a net negative event.

---

Analysis

The breadth of item codes here is what demands attention first. Item 3.03 specifically signals a material modification to the rights of security holders — this is not a minor housekeeping amendment. Combined with Item 5.03 (bylaws/articles changes), investors should scrutinize the actual exhibits attached to this filing for specifics on what rights have been altered, whether preferred share terms have changed, or whether anti-dilution or liquidation provisions have been modified. These structural changes can materially shift the risk/reward balance for common shareholders and often accompany financing transactions, restructurings, or strategic pivots.

On the financial side, the Q2 FY2026 numbers confirm that Gossamer Bio remains deeply pre-profitability. A -$0.33 EPS and a net loss approaching $36.6 million in a single quarter, with revenue of only $21.4 million, point to an operating burn that warrants close attention to the company's cash runway and any forthcoming capital raise disclosures.

Key things to watch:

• The precise language of any amendments filed under Items 3.03 and 5.03, particularly any changes affecting common shareholder voting rights or dilution protections
• Whether Item 8.01 references a specific transaction, partnership, or strategic development driving the governance changes
• The trajectory of revenue versus operating loss in subsequent quarters
• Any follow-on capital raise activity, which this type of corporate restructuring filing can sometimes precede

The nearly 7% intraday decline suggests institutional investors are not reading this as a neutral or positive development. Until the specifics of the rights modifications are fully parsed, the nature and magnitude of the changes remain the central open question.

---

Disclaimer

This report is a news and informational summary based solely on Gossamer Bio's 8-K filed with the SEC on September 11, 2026, and the structured XBRL data extracted directly from that filing. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is issued or implied. Readers should conduct their own due diligence and consult a qualified financial professional before making investment decisions.

Source

Filed with the SEC on 2026-09-11. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1728117/000172811726000094/goss-20260910.htm